Skip to main content


Log in

Switching anti-TNF-α agents: What is the evidence?

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript


The availability of biologic agents targeting tumor necrosis factor (TNF)-α represents a significant advance in the management of rheumatoid arthritis. Anti-TNF-α therapy has been associated with dramatic improvements in the clinical signs and symptoms of rheumatoid arthritis and has been shown to greatly retard the destructive process that too often characterizes this condition. Although effective and well-tolerated in a substantial proportion of patients, primary and secondary failures of anti-TNF-α strategies have been well described, affecting up to one-third to one-half of subjects treated with these agents. Switching from one anti-TNF-α agent to a second (or even third) anti-TNF-α therapy has emerged as a means of addressing treatment failures with this drug class. This review examines data addressing the practice of switching anti-TNF-α agents in the context of initial treatment failure, with a focus on data from peer-reviewed reports.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Furst D, Wallis R, Broder M, Beenhouwer D: Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006, 36:159–167.

    Article  PubMed  CAS  Google Scholar 

  2. Amgen and Wyeth: Enbrel [prescribing information]. Available at Accessed August 3, 2007.

  3. Centocor: Remicade [prescribing information]. Available at Accessed August 3, 2007.

  4. Knight D, Trinh H, Le J, et al.: Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993, 30:1443–1453.

    Article  PubMed  CAS  Google Scholar 

  5. Scallon B, Moore M, Trinh H, et al.: Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995, 7:251–259.

    Article  PubMed  CAS  Google Scholar 

  6. Sandborn W: Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep 2003, 5:501–505.

    Article  PubMed  Google Scholar 

  7. Maini R, Breedveld F, Kalden J, et al.: Therapeutic efficacy of multiple intravenous infusions of anti tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552–1563.

    Article  PubMed  CAS  Google Scholar 

  8. Abbott: Humira [prescribing information]. Available at Accessed August 3, 2007.

  9. Breedveld F, Weisman M, Kavanaugh A, et al.: The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26–37.

    Article  PubMed  CAS  Google Scholar 

  10. van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al.: Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006, 54:1063–1074.

    Article  PubMed  Google Scholar 

  11. Buch M, Bingham S, Bryer D, Emery P: Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford) 2007, 46:1153–1156.

    Article  CAS  Google Scholar 

  12. Keystone E: Switching tumor necrosis factor inhibitors: an opinion. Nat Clin Pract Rheumatol 2006, 2:576–577.

    Article  PubMed  Google Scholar 

  13. Gomez-Reino JJ, Carmona L, BIOBADASER Group: Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006, 8:R29.

    Article  PubMed  Google Scholar 

  14. van Vollenhoven R, Harju A, Brannemark S, Klareskog L: Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003, 62:1195–1198.

    Article  PubMed  Google Scholar 

  15. Haraoui B, Keystone E, Thorne J, et al.: Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004, 31:2356–2359.

    PubMed  CAS  Google Scholar 

  16. Hansen K, Hildebrand J, Genovese M, et al.: The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004, 31:1098–1102.

    PubMed  CAS  Google Scholar 

  17. Hyrich K, Lunt M, Watson K, et al.: Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:13–20.

    Article  PubMed  CAS  Google Scholar 

  18. Iannone F, Trotta F, Monteccuco C, et al.: Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 2007, 66:249–252.

    Article  PubMed  CAS  Google Scholar 

  19. Di Poi E, Perin A, Morassi M, et al.: Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab. Clin Exp Rheumatol 2007, 25:85–87.

    PubMed  Google Scholar 

  20. Buch M, Bingham S, Bejarano V, et al.: Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 2007, 57:448–453.

    Article  PubMed  CAS  Google Scholar 

  21. Solau-Gervais E, Laxenaire N, Cortet B, et al.: Lake of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford) 2006, 45:1121–1124.

    Article  CAS  Google Scholar 

  22. Nikas S, Voulgari P, Alamanos Y, et al.: Efficacy and safety of switching from infliximab to adalimumab: a comparative study. Ann Rheum Dis 2006, 65:257–260.

    Article  PubMed  CAS  Google Scholar 

  23. Bennett A, Peterson P, Zain A, et al.: Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology (Oxford) 2005, 44:1026–1031.

    Article  CAS  Google Scholar 

  24. Wick M, Ernestam S, Lindblad S, et al.: Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy to infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005, 34:353–358.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Alan R. Erickson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erickson, A.R., Mikuls, T.R. Switching anti-TNF-α agents: What is the evidence?. Curr Rheumatol Rep 9, 416–420 (2007).

Download citation

  • Published:

  • Issue Date:

  • DOI: